These findings are consistent with the current literature regarding ALDH1 as a CSC marker in NSCLC, and its role in resistance to molecular targeted therapies such as EGFR tyrosine kinase inhibitors [62]. Here, ALDH1A1 is linked to non-small cell lung carcinoma.